 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012
GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 1, 2011 / ProteoMonitor - UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer
April 20, 2012 / ProteoMonitor - Cellzome Snags More Than $3.1M in Grants for EU-, UK-Sponsored Research Initiatives
December 9, 2011 / ProteoMonitor - Proteomic Screen IDs Potential Use for GlaxoSmithKline Inhibitor in Treating Leukemia
October 7, 2011 / ProteoMonitor - AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 7, 2011 / ProteoMonitor